Insomnia in India — Types, Causes, and What Actually Works
By Fittour India Editorial Team
Reviewed by the Fittour India Editorial Team
Last updated: September 7, 2026
Roughly 1 in 3 Indian adults meets criteria for insomnia, and the figure climbs to 37% in adults over 60, according to a nationally representative study of older Indians published on PMC. Yet the treatment guidelines and the treatment reality in India point in opposite directions — cognitive behavioral therapy for insomnia (CBT-I) is the named first-line treatment in both Indian and international guidelines, while what most patients actually receive is a 10-minute prescription for a Schedule H1 sedative. This guide covers the real ICSD-3 types of insomnia, the causes that top-ranking global content skips (Indian shift-work data, joint-family and heat-driven sleep disruption), exactly which medications are legal and why, what a sleep study actually costs in India, and an evidence-ranked breakdown of what genuinely moves the needle versus what is marketing.
Quick Answer: Insomnia is difficulty falling asleep, staying asleep, or waking too early, occurring at least 3 nights a week. It is “short-term” under 3 months and “chronic” beyond that under ICSD-3 criteria. CBT-I is the guideline first-line treatment worldwide, more effective long-term than sleeping pills, but genuinely hard to access in India — most patients end up on zolpidem (Schedule H1, prescription-only) or, more often than guidelines recommend, a benzodiazepine.
What Are the Actual Types of Insomnia (ICSD-3 Classification)?
The International Classification of Sleep Disorders, Third Edition (ICSD-3) recognizes three insomnia categories, and the distinction changes what treatment makes sense.
| Type | Duration / frequency | What it looks like | India prevalence |
|---|---|---|---|
| Short-term (acute) insomnia | Under 3 months, any frequency | Tied to an identifiable stressor — exam, job change, travel, illness, grief | Most common; usually self-resolves |
| Chronic insomnia disorder | 3+ months, 3+ nights/week | Persistent, causes daytime impairment (fatigue, mood, concentration), often outlasts the original trigger | 25.7% pooled prevalence in the general population per a 100-study systematic review — medRxiv systematic review of sleep problems in India |
| Other insomnia disorder | Symptoms present but don’t fully meet chronic or short-term criteria | A catch-all diagnostic category for atypical presentations | Not separately tracked in Indian data |
Takeaway: The single most useful number in this table is “1 in 5” — nearly a fifth of short-term insomnia cases progress into chronic insomnia disorder, per a PMC review on acute versus chronic insomnia mechanisms. The real window to act is during the acute phase, not after it has already become chronic.
⚠️ What most people get wrong here: Treating “a few bad weeks of sleep” as something to just wait out. Acute insomnia untreated is exactly how a stress-triggered sleep problem turns into a standalone chronic condition that outlives the original stressor by months or years.
Insomnia is also classified by symptom pattern, independent of duration:
- Sleep-onset insomnia — trouble falling asleep (typically over 20-30 minutes to fall asleep)
- Sleep-maintenance insomnia — falling asleep fine but waking repeatedly through the night
- Early-morning awakening — waking 1-2+ hours before the intended time and being unable to fall back asleep, often a marker of depression
- Mixed insomnia — a combination of the above, most common in chronic cases
What Actually Causes Insomnia — Beyond “Stress and Screens”
Generic content stops at “stress, caffeine, screens.” The real causal map is broader and, in India, has some distinctly local drivers.
| Category | Examples | India-specific note |
|---|---|---|
| Psychiatric | Anxiety disorders, depression, PTSD | Insomnia is bidirectional with both — see the Anxiety Disorders in India pillar guide and the Depression in India guide |
| Medical/hormonal | Hyperthyroidism, chronic pain, GERD, menopause, obstructive sleep apnea | Hyperthyroidism specifically causes hyperarousal insomnia — covered in the thyroid problems in India pillar |
| Medication-induced | SSRIs (activation window), steroids, some decongestants, high-dose caffeine-containing analgesics | Escitalopram and other SSRIs can transiently worsen sleep in the first 2-4 weeks — see the escitalopram medicine page |
| Behavioral/environmental | Irregular sleep-wake times, late heavy meals, alcohol, blue light, noise | Indian-specific: joint-family co-sleeping and shared-room noise, inconsistent AC access during summer heat |
| Occupational | Shift work, jet lag | India’s IT/BPO night-shift workforce is a major, under-discussed driver — see below |
| Substance-induced | Caffeine, nicotine, alcohol withdrawal rebound | Caffeine’s half-life runs 2-10 hours depending on the individual — see the FAQ on chai/coffee timing below |
Takeaway: Roughly half of chronic insomnia in adults traces back to an untreated psychiatric or medical cause rather than “bad sleep habits” alone — which is why sleep hygiene advice alone often fails to fix chronic cases.
The India-specific driver almost no competitor article covers: shift work
An Indian hospital-based study found 83.3% of night-shift nursing staff had mild-to-moderate shift work sleep disorder, and a separate cohort study of Indian night-shift workers found that none of the participants scored as having good sleep quality on standard measures — Indian Journal of Psychiatric Nursing shift work study, study on night shift work and sleep quality. With India’s IT-BES/BPO sector employing millions on US-hours schedules, circadian misalignment is a mainstream cause of insomnia here, not a niche occupational-health footnote. The depression and burnout in India’s IT sector article covers the broader mental-health toll of this work pattern.
📊 What the research shows: Roughly 300 of the 3,500-4,000 daily calls to a major Indian mental-health helpline are sleep-related, according to Deccan Herald reporting on sleep deprivation and mental health emergencies — sleep disruption is one of the top three triggers driving people to call in the first place.
Is Insomnia Diagnosed With a Sleep Study? What It Actually Costs in India
Most insomnia does not need a polysomnography (sleep study) to diagnose — it is a clinical diagnosis based on sleep history, a sleep diary, and screening for underlying causes. A sleep study becomes relevant when your doctor suspects a coexisting condition like obstructive sleep apnea (loud snoring, witnessed breathing pauses) or periodic limb movement disorder.
| Test type | Setting | Typical India cost | When it’s actually needed |
|---|---|---|---|
| Home sleep apnea test (Level 3) | At home, portable device | ₹2,999-8,000 | Suspected sleep apnea, no complex comorbidities |
| In-lab polysomnography (Level 2/1) | Hospital sleep lab, overnight, technician-monitored | ₹8,000-18,000 | Suspected apnea plus other disorders, inconclusive home test, planned CPAP titration |
| Full attended PSG, metro premium centres | Tertiary hospital, Delhi/Mumbai/Bengaluru | Up to ₹30,000 | Complex cases, pre-surgical clearance, narcolepsy workup |
Takeaway: If a clinic recommends an expensive sleep study before even trying a structured sleep-history assessment or CBT-I for straightforward insomnia symptoms, get a second opinion — it is a diagnostic step for suspected sleep apnea and related disorders, not a routine insomnia test. Cost ranges compiled from Remesleep’s 2026 India sleep study cost breakdown and CARE Hospitals’ sleep study cost page.
CBT-I Is the Guideline First-Line Treatment — So Why Can’t Most Indians Access It?
Cognitive behavioral therapy for insomnia (CBT-I) is named the first-line treatment for chronic insomnia by both the Indian Psychiatric Society’s Clinical Practice Guidelines for Sleep Disorders and the API-ISSR Indian Consensus Statement referenced in a 2026 expert review on insomnia management published in Sleep and Vigilance. A major meta-analysis of 20 studies covering 1,162 patients, published in the Annals of Internal Medicine, found CBT-I produced significant, durable improvements across sleep-onset latency, wake-after-sleep-onset, total sleep time, and sleep efficiency — Annals of Internal Medicine CBT-I systematic review and meta-analysis.
The 5 components of CBT-I
- Sleep education — understanding sleep architecture and homeostatic sleep drive
- Stimulus control therapy — using the bed only for sleep (and sex), getting out of bed if not asleep within ~20 minutes
- Sleep restriction therapy — temporarily limiting time in bed to match actual sleep time, then gradually extending it as efficiency improves
- Cognitive restructuring — addressing catastrophic thoughts about sleep loss (“I’ll be useless tomorrow”) that themselves cause hyperarousal
- Relaxation training — progressive muscle relaxation, breathing techniques to lower pre-sleep physiological arousal
⚠️ What most people get wrong here: Assuming CBT-I is the same as generic “sleep hygiene” advice (dim lights, no phone, cool room). Sleep hygiene is one small supporting piece; sleep restriction and stimulus control — the components that actually retrain the brain’s association with the bed — are the parts that require structured, often uncomfortable, weekly guidance most people won’t self-administer correctly.
The access gap is real and mirrors what fittour has already documented in the anxiety-treatment space: very few Indian psychologists are specifically trained in CBT-I protocols, so it rarely gets offered even where general therapy is available. The CBT therapist vetting directory built for anxiety treatment applies the same vetting logic here — ask any prospective therapist directly whether they are trained in CBT-I specifically, not general CBT. Government tertiary centres with dedicated sleep clinics, such as the Sleep Disorders Clinic referenced in the NIMHANS Bengaluru walk-in guide, are among the few low-cost access points in the country. Digital CBT-I programs are an emerging option, though a fully automated app-based version shows smaller effects than therapist-supported CBT-I according to recent digital-CBT-I meta-analyses.
If a dedicated CBT-I clinic isn’t within reach, India’s free government mental health infrastructure is a genuinely underused fallback — our free depression treatment and government mental health services guide covers DMHP district psychiatry OPDs and the national Tele-MANAS helpline (14416), both of which can support sleep-related complaints alongside mood disorders at no cost.
What Medications Are Actually Prescribed for Insomnia in India — And What’s Legal
This is where India’s regulatory reality diverges sharply from generic global content.
| Medication class | Examples (Indian brands) | Legal status in India | Dependence risk | Typical monthly cost |
|---|---|---|---|---|
| Z-drugs | Zolpidem (Stilnoct, Zolfresh), zopiclone | Schedule H1 — prescription mandatory, pharmacy must log sale | Moderate with prolonged use | ₹150-400 |
| Benzodiazepines | Clonazepam (Rivotril, Lonazep), alprazolam, lorazepam | Schedule H1 (some), NDPS-adjacent restrictions | Higher, especially beyond 2-4 weeks | ₹50-300 |
| Melatonin | Various supplement brands | Over-the-counter, unregulated as a drug | Minimal | ₹200-600 |
| Sedating antidepressants (low-dose) | Mirtazapine, trazodone, amitriptyline | Prescription (not H1-restricted) | Low | ₹80-250 |
| Antihistamines (sedating) | Hydroxyzine (Atarax) | Prescription, less restricted | Low, but tolerance builds fast | ₹60-150 |
Takeaway: Zolpidem’s legal restriction is not bureaucratic friction — India’s Drugs Technical Advisory Board has explicitly and recently reaffirmed Schedule H1 status for zolpidem after an industry petition to loosen it, specifically citing dependence risk, per Medical Dialogues’ report on the DTAB ruling.
The prescribing pattern gap
An observational Indian study found 73.7% of insomnia prescriptions were benzodiazepines versus only 26.3% zolpidem — PMC observational study on sedative-hypnotic prescribing in India — even though guidelines generally favor zolpidem’s shorter action profile for short-term insomnia. This matters directly to readers coming from anxiety treatment: the same benzodiazepines routinely prescribed for sleep are the ones documented in the Clonazepam Trap tapering journal, where CBT-I is one of the interventions used to manage sleep during benzodiazepine withdrawal.
⚠️ What most people get wrong here: Assuming a prescription sleeping pill is a long-term solution. Guidelines universally cap benzodiazepine and Z-drug use at 2-4 weeks for insomnia. Beyond that window, tolerance builds, effectiveness drops, and the dependence risk climbs — turning a temporary sleep problem into a second, medication-dependence problem.
Melatonin, Ashwagandha, and Ayurvedic Options — What the Evidence Actually Shows
| Option | Evidence grade | Typical studied dose | What it actually helps |
|---|---|---|---|
| Melatonin | Moderate for circadian issues, weak for classic insomnia | 0.5-3 mg, 1-2 hours before target bedtime | Jet lag, shift-work circadian misalignment, delayed sleep phase — not a strong sedative |
| Ashwagandha | Small but significant effect (meta-analysis) | 300-600 mg standardized root extract, daily, 6-8 weeks | Sleep efficiency, sleep onset latency, total sleep time — most pronounced in diagnosed insomnia |
| Jatamansi | Traditional use, limited controlled trial data | Varies by formulation | Sedative/anxiolytic effect reported in small studies; needs more RCT evidence |
| Brahmi | Preliminary evidence | Varies by formulation | May support non-REM sleep depth; primarily anxiety-reduction evidence |
Takeaway: Melatonin is genuinely OTC in India — unlike several other countries where it is prescription-controlled — but that same lack of prescription-drug oversight means labelled Indian melatonin doses are not independently verified for accuracy the way a Schedule H1 drug’s manufacturing is.
The ashwagandha finding comes from a meta-analysis of 5 randomized controlled trials (400 total participants) — PLOS ONE systematic review and meta-analysis of ashwagandha and sleep — cross-checked against the NIH Office of Dietary Supplements’ ashwagandha fact sheet, which still classifies the overall evidence base as preliminary rather than conclusive. Full brand comparisons, dosing detail, and drug-interaction cautions are in the ashwagandha medicine page — worth reading in full before choosing a specific product, since Indian ashwagandha brands vary considerably in standardized withanolide content.
The Behavioral Basics: Caffeine Timing, Blue Light, and What’s Actually Backed by Evidence
Two of the most repeated pieces of sleep advice online deserve a harder look.
Caffeine timing. Caffeine’s half-life ranges from 2 to 10 hours depending on genetics and liver metabolism, and controlled research shows even 100-200 mg — roughly one strong filter coffee or two cups of chai — consumed 6 hours before bed measurably increases sleep-onset time, per a randomized crossover trial published in SLEEP (Oxford). A blanket “no coffee after dinner” rule underestimates this for slow metabolizers — a noon or early-afternoon cutoff is more realistic for anyone with existing insomnia symptoms, given how central chai and filter coffee are to the Indian day.
Blue light glasses. The evidence is a genuine coin flip, not the universal fix marketing suggests. A 2025 systematic review and meta-analysis of randomized crossover trials on blue-light-blocking glasses found roughly half the trials showed a sleep benefit and half showed none — Frontiers in Neurology systematic review on blue-light-blocking glasses. Screen engagement and delayed bedtime themselves appear to matter as much as blue wavelength specifically. A stricter cutoff — no screens 60-90 minutes before bed — is the more reliably evidence-backed intervention than wearing glasses while continuing to scroll.
⚠️ What most people get wrong here: Buying blue-light glasses as a substitute for actually reducing screen time before bed, when the research suggests the glasses alone often don’t move the needle.
What Actually Works — Ranked by Evidence Strength
| Intervention | Evidence strength | Best for | Access in India |
|---|---|---|---|
| CBT-I (therapist-led) | Strongest, most durable | Chronic insomnia, any cause | Very limited — few trained providers |
| Stimulus control + sleep restriction (self-applied from CBT-I principles) | Strong | Chronic insomnia, self-motivated patients | Free, but requires discipline and often a rough 1-2 week adjustment |
| Zolpidem (short-term, supervised) | Strong short-term, weak long-term | Short-term/acute insomnia, situational | Requires prescription (Schedule H1); ₹150-400/month |
| Treating the underlying cause (thyroid, anxiety, depression, apnea) | Strong when a cause is identified | Secondary insomnia | Depends on diagnosis; often the actual fix |
| Ashwagandha | Modest, evidence-supported | Mild-moderate insomnia, adjunct use | Widely available OTC |
| Melatonin | Modest, circadian-specific | Jet lag, shift work, delayed sleep phase | Widely available OTC, dosing not independently verified |
| Sleep hygiene alone | Weak-to-modest on its own | Prevention, mild cases | Free |
| Benzodiazepines (long-term) | Weak long-term, real dependence cost | Not recommended beyond 2-4 weeks | Overprescribed relative to guidelines |
| Blue-light glasses alone | Inconclusive | — | Widely marketed, evidence mixed |
Takeaway: The two most effective options — CBT-I and treating an underlying medical or psychiatric cause — are also the two most underused in India, while the least durable option (long-term benzodiazepines) remains the most commonly prescribed.
Sources & References
- PMC — Prevalence and predictors of insomnia among older adults in India
- medRxiv — Systematic Review of Prevalence of Sleep Problems in India
- ScienceDirect — International Classification of Sleep Disorders, Third Edition
- PMC — Acute and Chronic Insomnia: What Has Time and/or Hyperarousal Got to Do With It?
- Indian Psychiatric Society — Clinical Practice Guidelines for Sleep Disorders
- Sleep and Vigilance — Expert Opinion on Diagnosis and Management of Insomnia: An Indian Perspective
- Annals of Internal Medicine — Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis
- Medical Dialogues — DTAB Rules Zolpidem Continues to Be Schedule H1 Drug
- PMC — Effects of Sedative-Hypnotics on Sleep Quality Among Patients With Insomnia: India
- Remesleep — Sleep Study Test Cost in India 2026
- CARE Hospitals — Sleep Study Test Cost
- PLOS ONE — Effect of Ashwagandha Extract on Sleep: A Systematic Review and Meta-analysis
- NIH Office of Dietary Supplements — Ashwagandha Fact Sheet for Health Professionals
- SLEEP (Oxford Academic) — Dose and Timing Effects of Caffeine on Subsequent Sleep
- PMC/Frontiers in Neurology — Efficacy of Blue-Light Blocking Glasses on Sleep Outcomes
- Indian Journal of Psychiatric Nursing — Prevalence of Shift Work Sleep Disorder
- Deccan Herald — Sleep Deprivation a Major Trigger for Mental Health Emergency